Related Experiment Video

Updated: Feb 5, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors]

Rilan Bai1, Naifei Chen1, Jiuwei Cui1

  • 1Cancer Center, the First Hospital of Jilin University, Changchun 130021, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|September 3, 2018
PubMed

Insights

Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) are first-line for EGFR-mutant non-small cell lung cancer (NSCLC), but resistance emerges. Immune checkpoint inhibitors show limited efficacy in these patients, necessitating novel therapeutic strategies.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) are standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
  • Acquired resistance to TKIs is a significant clinical challenge, limiting long-term efficacy.
  • Immune checkpoint inhibitors (ICIs) have transformed NSCLC treatment, but their efficacy in EGFR-mutant NSCLC is suboptimal.

Purpose of the Study:

  • To review the immune microenvironment in EGFR-mutant NSCLC.
  • To discuss the current status and challenges of immune checkpoint inhibitors (ICIs) in this patient population.
  • To explore combination strategies involving TKIs and ICIs for EGFR-mutant NSCLC.

Main Methods:

  • Literature review of studies on EGFR-mutant NSCLC, TKI resistance, and ICI efficacy.
  • Analysis of factors contributing to poor ICI response, including PD-L1 expression and tumor microenvironment.
  • Examination of emerging combination therapies.

Main Results:

  • EGFR mutations are associated with specific immune microenvironment characteristics that may impair ICI efficacy.
  • Low PD-L1 expression, an immunosuppressive tumor microenvironment, and low tumor mutation burden are implicated in poor responses to ICIs.
  • Combination of TKIs and ICIs is being investigated to overcome resistance and improve outcomes.

Conclusions:

  • Understanding the immune microenvironment is crucial for optimizing NSCLC treatment.
  • Novel therapeutic approaches combining TKIs with ICIs hold promise for EGFR-mutant NSCLC.
  • Further research is needed to enhance the efficacy of immunotherapies in this subset of NSCLC patients.
Keywords:
EGFR mutationImmune checkpoint inhibitorsLung neoplasmsPD-L1

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.3K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Mutations01:39

Mutations

Overview
94.5K
The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.9K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K